Animalcare Group Valuation

Q: What is the Fair Price of WQ7 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

WQ7 (€2.76) is trading below our estimate of [[fair value]] (€3.39)

Is WQ7 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of WQ7 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: WQ7 (€2.76) is trading below our estimate of fair value (€3.39)

Significantly Below Fair Value: WQ7 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for WQ7?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for WQ7. This is calculated by dividing WQ7's market cap by their current preferred multiple.
What is WQ7's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	UK£143.69m

WQ7 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.5x
Enterprise Value/EBITDA	11.3x
PEG Ratio	2x

Price to Earnings Ratio vs Peers

How does WQ7's PE Ratio compare to its peers?

The above table shows the PE ratio for WQ7 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	20.7x
PSG PharmaSGP Holding	14.1x	13.6%	€256.6m
2FJ0 Pierrel	29.9x	n/a	€92.8m
93M1 MPH Health Care	3.6x	8.4%	€104.5m
B8FK Biofrontera	35.3x	n/a	€14.1m
WQ7 Animalcare Group	31.1x	15.8%	€143.7m

Price-To-Earnings vs Peers: WQ7 is expensive based on its Price-To-Earnings Ratio (31.1x) compared to the peer average (20.7x).

Price to Earnings Ratio vs Industry

How does WQ7's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.4%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: WQ7 is expensive based on its Price-To-Earnings Ratio (31.1x) compared to the European Pharmaceuticals industry average (22.3x).

Price to Earnings Ratio vs Fair Ratio

What is WQ7's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

WQ7 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	31.1x
Fair PE Ratio	12.6x

Price-To-Earnings vs Fair Ratio: WQ7 is expensive based on its Price-To-Earnings Ratio (31.1x) compared to the estimated Fair Price-To-Earnings Ratio (12.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst WQ7 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	€2.76	€3.64 +32.0%	4.4%	€3.81	€3.48	n/a	2
Sep ’25	€3.10	€3.61 +16.6%	4.4%	€3.77	€3.45	n/a	2
Aug ’25	€3.22	€3.61 +12.2%	4.4%	€3.77	€3.45	n/a	2
Jul ’25	€2.64	€3.43 +30.1%	8.0%	€3.71	€3.16	n/a	2
Jun ’25	€2.72	€3.43 +26.2%	8.0%	€3.71	€3.16	n/a	2
May ’25	€2.62	€3.43 +31.0%	8.0%	€3.71	€3.16	n/a	2
Apr ’25	€2.32	€3.74 +61.4%	6.3%	€3.98	€3.51	n/a	2
Mar ’25	€2.44	€3.74 +53.5%	6.3%	€3.98	€3.51	n/a	2
Feb ’25	€2.00	€3.74 +87.2%	6.3%	€3.98	€3.51	n/a	2
Jan ’25	€1.86	€3.68 +97.9%	6.3%	€3.91	€3.45	n/a	2
Dec ’24	€1.94	€3.68 +89.7%	6.3%	€3.91	€3.45	n/a	2
Nov ’24	€1.90	€3.68 +93.7%	6.3%	€3.91	€3.45	n/a	2
Oct ’24	€1.96	€3.68 +87.8%	6.3%	€3.91	€3.45	n/a	2
Sep ’24	€1.94	€4.03 +107.6%	4.5%	€4.21	€3.85	€3.10	2
Aug ’24	€1.87	€4.03 +115.4%	4.5%	€4.21	€3.85	€3.22	2
Jul ’24	€2.02	€3.79 +87.8%	1.2%	€3.84	€3.75	€2.64	2
Jun ’24	€2.02	€3.79 +87.8%	1.2%	€3.84	€3.75	€2.72	2
May ’24	€1.99	€3.79 +90.7%	1.2%	€3.84	€3.75	€2.62	2
Apr ’24	€1.72	€3.79 +120.6%	1.2%	€3.84	€3.75	€2.32	2
Mar ’24	€1.90	€3.99 +110.0%	4.3%	€4.16	€3.82	€2.44	2
Feb ’24	€1.93	€3.99 +106.7%	4.3%	€4.16	€3.82	€2.00	2
Jan ’24	€2.42	€4.33 +79.0%	5.8%	€4.58	€4.08	€1.86	2
Dec ’23	€2.46	€4.33 +76.1%	5.8%	€4.58	€4.08	€1.94	2
Nov ’23	€2.44	€4.33 +77.5%	5.8%	€4.58	€4.08	€1.90	2
Oct ’23	€2.72	€4.33 +59.3%	5.8%	€4.58	€4.08	€1.96	2
Sep ’23	€3.28	€5.24 +59.8%	1.9%	€5.34	€5.14	€1.94	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.